Bringing the fundamentals into focus…
Back to Repligen Corporation
How Repligen Corporation stacks up
RGEN · against 1,336 other Healthcare companies
Valuation
37/ 100
Below the middle of the pack.
Ranked #837 of 1,337 · scores higher than 37% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 30–39, including RGEN · Click a bar to see the companies
Why valuation scores 37?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 63% of peers. EBITDA yield: 1.5% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 0.4% vs peer median 1.5%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.1% vs peer median 0.0%
Metric by metric
Position: dot = RGEN, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RGEN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 0.4% | 1.5% | 42% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 1.4% | 4.2% | 37% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 1.1% | -1.0% | 58% | 20% | |
| Book yieldHigher is better · 1,306 reported | 21.0% | 37.9% | 30% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around RGENScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score